ORCID Profile
0000-0002-2621-9284
Current Organisation
Queensland University of Technology
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Springer Science and Business Media LLC
Date: 19-02-2014
DOI: 10.1007/S12032-014-0881-Z
Abstract: The purpose of this study was to compare toxicity rates and types between obese and non-obese women during adjuvant chemotherapy for breast cancer, adjusting for regimen type and received dose. We conducted a retrospective cohort study of 537 women receiving chemotherapy, initially treated between 2007 and 2010 at two tertiary hospitals in Brisbane, Australia. Demographic, chemotherapy and toxicity data were extracted from patient charts and analyzed using multivariate logistic regression. Three hundred and seventy-four women were eligible for inclusion. Obese women (body mass index (BMI) > 30 kg/m(2) mean age 52.58 ± 9.49) were older than non-obese women (BMI ≤ 29.9 kg/m(2) mean age 50.19 ± 11.15, P = 0.05) and had more comorbidities (P < 0.01). After adjustment for potential confounders, obesity was not statistically related to chemotherapy-related admission risk (OR 1.27 95 % CI 0.78-2.09) or febrile neutropenia risk (OR 0.56 95% CI 0.28-1.21). However, obese women received chemotherapy with proportionally lower mean relative dose intensity than non-obese women (94 vs. 97% of reference dose, P = 0.03). Eighteen (15.8%) obese and zero non-obese women (P < 0.01) had their chemotherapy dose capped at an arbitrary body surface area. Compared with non-obese women, obese women receive different chemotherapy regimens and relatively lower chemotherapy doses. There was no significant evidence of increased toxicity among obese women with either full or adjusted chemotherapy doses. Full body surface areas-based dosing appears to be tolerated as well in obese as in lean women.
Publisher: Future Medicine Ltd
Date: 11-2019
Abstract: This review summarizes the utility of 3D-printing as a surgical adjunct, reviewing the cost–effectiveness. The relevant literature was analyzed outlining the utility and/or cost–effectiveness of 3D-printing for clinical use. Compared with existing methods, the evidence suggests an advantage of using 3D-printing as a technology in the treatment of complex clinical cases. However, in high frequency cases, the additional preoperative expenses are not justified. Considerable evidence of its clinical benefits exists for the application of 3D-printed anatomical models and teaching tools. However, the evidence supporting 3D-printing’s use as surgical guides or implantable devices is less clear. Furthermore, caution must exist when using these devices in the clinical setting due to a paucity of rigorous testing, global regulation and long-term data.
Publisher: Elsevier
Date: 2017
Publisher: Mary Ann Liebert Inc
Date: 06-2021
Publisher: Informa UK Limited
Date: 19-02-2016
DOI: 10.3109/02656736.2015.1137640
Abstract: The aim of this study was to evaluate radiofrequency ablation (RFA) and microwave ablation (MWA) as a viable salvage option for patients with locally recurrent non-small cell lung cancer (NSCLC) after radiotherapy. This retrospective study was conducted on patients who had received thermal ablation for recurrent NSCLC post-curative radiotherapy. Medical records and follow-up imaging with computed tomography (CT) and PET-CT were analysed to determine time to local progression (TTLP) and overall survival (OS). TTLP was determined according to the modified RECIST criteria. Twelve patients, mean age 71 ± 7 years, received 17 thermal ablation sessions, with RFA performed for four lesions and MWA for 13. Nine tumours were squamous cell cancers (SCC) and eight were adenocarcinomas. Eleven tumours had recurred post-external beam radiation and one post-stereotactic body radiation therapy. Mean tumour size was 34.2 ± 12.8 mm, tumour stages prior to radiotherapy were Ia (2), Ib (3), IIa (4), IIb (1) and III (2). Follow-up period was 19 ± 11 months. Overall median TTLP was 14 months (95% CI: 8, 19), and median OS was 35 months (95% CI: 12, 58). Mean TTLP for tumours 30 mm 14 months (p = 0.20). Recurrence rates reduced from 50% after initial ablation to 20% with a second ablation. Complication rate for pneumothorax requiring intervention was 17%. Both RFA and MWA ablation prolonged local tumour control with minimal morbidity in this study group of recurrent NSCLC after radiotherapy.
Publisher: Mary Ann Liebert Inc
Date: 06-2017
No related grants have been discovered for Matthew Cheng.